Yissum - Research Development Company of the Hebrew University posted this:Treatment of Genetic Diseases Caused by Nonsense MutationTreatment of Genetic Diseases Caused by Nonsense Mutation Project ID : 6-2018-4579
Lucas Montes posted this:
Technology Transfer Advisor at University of Granada (OTRI)
Yissum - Research Development Company of the Hebrew University posted this:Novel Indoline Derivatives with Antioxidant and Anti-Inflammatory ActivityNovel Indoline Derivatives with Antioxidant and Anti-Inflammatory Activity Project ID : 7-2015-3171
Yissum - Research Development Company of the Hebrew University posted this:Novel Transdermal Delivery System of CannabinoidsCannabinoids Transdermal, enhanced and modulated administration due to an innovative biphasic composition Project ID : 6-2016-4334
Universidad de Alcalá-OTRI posted this:Carbosilane dendrons functionalized with fatty acids: Formation of micelles and uses in biomedicine as antiviral, antibacterial, antiprionic, antimicrobial and drug transporters.The research group of the University of Alcalá in «Dendrimers for biomedical applications» presents the following invention that refers to the formation of dendrons of carbosilane structure that have in their periphery preferably anionic or cationic groups and in the focal point fatty acids or derivatives of these. Its main field of application is in biomedicine, as non-viral transport agents, as drug transporters, to elaborate a drug, as antimicrobial, antiviral or antipyretic agents. In the environmental sector we also find its application as biocides for water treatment. The group seeks to reach license agreements, collaboration or commercial agreements with technical assistance with companies from the sector of Health, Pharma and Environment.
Yissum - Research Development Company of the Hebrew University posted this:Products for Preventing Penetration Into the SkinKeywords: cosmetics, sunscreens Project ID : 6-2006-191
Yissum - Research Development Company of the Hebrew University posted this:Treatment Of Hepatic Encephalopathy And Liver CirrhosisA method for the treatment of hepatic encephalopathy comprising administering to a subject in need of such treatment an effective amount of D9-tetrahydrocannabinol (THC) or Cannabidiol. keywords: hepatic, encephalopathy Originally: 12-2007-1885, 12-2007-1878 12-2006-577- 3 projects combined into one Project ID : 12-2006-577
Yissum - Research Development Company of the Hebrew University posted this:Novel Compounds for the treatment of obesityNovel Compounds for the treatment of obesity Project ID : 6-2008-1996
Yissum - Research Development Company of the Hebrew University posted this:Floating sustained release of antioxidantsFloating Sustained Release Delivery systems of Polyphenols Project ID : 6-2009-2215
Yissum - Research Development Company of the Hebrew University posted this:Novel Compounds for the Treatment and Prevention of Autismbeta- carotene as treatment for autism Project ID : 6-2014-3058
Yissum - Research Development Company of the Hebrew University posted this:New Formulations for Oral, Nasal, Transdermal and Rectal CannabinoidsCBD Project ID : 6-2017-4448
Yissum - Research Development Company of the Hebrew University posted this:Treating Skin Toxicities Caused by Biological Cancer Drugs Applying Topical Specific Inhibitors to the Anti-Cancer DrugsMany of the antineoplastic tyrosine kinase inhibitors are associated with prominent and sometimes dose-limiting dermatologic complications. Of severe clinical implication are the specific EGFR inhibitors. Most patients treated with these drugs suffer from severe impairment to their quality of life and require reduction or interruption in the anti-cancer drug protocols. Treatment strategies today for treating skin toxicities from EGFR inhibitors show limited benefit and most patients require dose reductions or interruptions to the anti-cancer treatment protocols. Our proposal focuses on the development of a novel approach using formulation for treating skin toxicities caused by anti-neoplastic EGFR inhibitors by applying topical compounds that specifically and locally block the anti-cancer drugs. Our preliminary results have shown that blocking EGFR inhibitors binding to EGFR prevents keratinocyte death. We have identified small compounds that block EGFR inhibitors binding to its receptor and have developed topical slow release system that can deliver the target compounds to the hair follicle which is a major target for skin rash caused by EGFR inhibitors. Our novel approach will improve the quality of life of patients suffering from skin toxicity and help maintain an optimal anti-neoplastic dose thereby allowing more patients to receive full dose anti-cancer therapy and improve response to therapy Project ID : 6-2017-4450
Yissum - Research Development Company of the Hebrew University posted this:Novel Autotaxin Inhibitor Drug (XIIPHONATE) for Cancer and/or AsthmaWe propose a novel compound for the treatment of asthma. We suggest to use this new compound named XIIPHONATE as new lipid-mimetic molecule that inhibits recombinant Autotaxin (ATX), as a potential local, long-term treatment for asthma. This approach is based on the fact that a novel bioactive lipid mediator, Lysophosphatidic acid (LPA), has a pivotal role in the pathogenesis of asthma. It was reported that LPA is synthesized from LPC through the enzymatic activity of ATX. Clinical data show that the levels of ATX protein, and LPA are significantly elevated the in airspaces of patients with asthma. Thus, XIIPHONATE, will inhibit LPA overproduction that leads to the pathologic state. It will therefore present a new therapeutic modality for asthma. Project ID : 6-2016-4268
Merck KGaA posted this:Technology for Serum and Glucocorticoid regulated kinase (SGK) inhibitorsMerck KGaA, Darmstadt, Germany, has developed and patented the results of its intense R&D activities for the identification of small organic molecules as SGK1 inhibitors. Based upon a rational screening cascade established, compounds have been identified and characterized with regard to their specific in vitro, cellular and in vivo activities. The package includes access to the IP, experimental results, and materials. Merck KGaA, Darmstadt, Germany, offers the unique chance to acquire this promising program.
Fundació URV posted this:Improving the efficacy of autologous stem cell transplantation from adipose tissue in patients with Crohn's diseaseThe invention relates to a method for obtaining stem cells with immunomodulatory properties derived from adipose tissue. The invention presents relevant applications in order to cure or improve Crohn's disease (EC) and the resulting complications such as perianal fistulas using cellular therapy.